The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease

Clin Immunol. 2020 Oct:219:108541. doi: 10.1016/j.clim.2020.108541. Epub 2020 Jul 15.


Immune modulation with rituximab, methotrexate, and intravenous immunoglobulin (IVIG) has shown great success in inducing immune tolerance in a large cohort of enzyme replacement therapy (ERT)-naïve infantile Pompe disease patients. Antibody-dependent cellular cytotoxicity, the principal mechanism by which rituximab depletes B-cells, requires CD20 binding by Fab'2 of rituximab on B-cells and the concomitant binding of its Fc region to Fc receptors on effector cells or to complement. To protect patients against microbial infections when using rituximab, IVIG was added to the immunomodulation regimen used in Pompe disease. Administration of IVIG can saturate neonatal Fc receptors (FcRn), which recycle endogenous as well as administered polyclonal/monoclonal antibodies via the binding of the Fc moiety to FcRn. As such, the administration of IVIG prior to rituximab, a chimeric mouse-human monoclonal antibody, may sharply reduce the half-life of rituximab and in turn, its efficacy. Based on this understanding, it is vital to understand the optimal timing of IVIG administration in relation to rituximab administration for the purposes of inducing immune tolerance.

Keywords: Anti-drug antibodies; Anti-rhGAA IgG antibodies; Enzyme replacement therapy; Immunomodulation; Pompe disease.

Publication types

  • Letter

MeSH terms

  • Glycogen Storage Disease Type II / drug therapy*
  • Glycogen Storage Disease Type II / immunology
  • Humans
  • Immune Tolerance / drug effects
  • Immunoglobulins, Intravenous / administration & dosage*
  • Immunologic Factors / administration & dosage*
  • Rituximab / administration & dosage*
  • Treatment Outcome


  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Rituximab